Navigation Links
Eisai Joins Groundbreaking Tuberculosis Drug Accelerator Partnership to Discover New Tuberculosis Drugs
Date:11/25/2013

TOKYO, Nov. 25, 2013 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has become a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, a groundbreaking initiative that aims to speed up the discovery of essential new treatments for tuberculosis (TB).

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

Jointly launched in June 2012 through a collaborative agreement among seven pharmaceutical companies1 and six research institutions2 with support from the Bill & Melinda Gates Foundation, the TBDA partnership targets the discovery of new TB drugs by working together on early-stage research. The long-term goal of the partnership is to create a new TB drug combination that has the potential to cure patients in only one month, compared to the six months of treatment required by existing drugs. Based on the partnership, the participating pharmaceutical companies will open up targeted sections of their compound libraries and share data with other participating pharmaceutical companies and research institutions. As a TBDA member, Eisai will provide selected portions of its chemical library for screening against TB as well as share identified and confirmed hits with other TBDA partners. Eisai will also work cooperatively with other partners to facilitate the development of new therapies for TB.

TB is a contagious disease caused by a bacterial infection that affects the lungs and other organs.  Although it is a curable and preventable disease, it is the second leading infectious cause of death worldwide, having resulted in the deaths of 1.4 million people in 2011 alone. One of the main reasons for the high mortality is that first-line therapies for TB are antiquated and inadequate, with all existing drugs being at least 50 years old and requiring at least six months to cure the disease. Furthermore, the length of the existing TB treatments means that a considerable number of patients drop out before completion, which in turn can lead to further transmission, emergence of drug resistance, and death. By discovering a new TB drug combination with the potential to cure patients in one month, the TBDA will contribute to shortening the length of treatment as well as decreasing treatment default rates.

Eisai is committed to improving the health and welfare of people in developing and emerging countries and considers its contributions to the economic development and expansion of the middle-income class through these endeavors as a form of long-term investment for future market growth. To achieve this, Eisai remains actively committed to addressing issues in global health to further increase the benefits provided to patients and their families worldwide.

1 AbbVie, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck, Sanofi

2 Infectious Disease Research Institute, National Institute of Allergy and Infectious Diseases, Rutgers University, Texas A&M University, University of Dundee, Weill Cornell Medical College

Media Inquiries:  
Public Relations Department,  
Eisai Co., Ltd.  
+81-(0)3-3817-5120

 

 


'/>"/>
SOURCE Eisai Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
2. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
3. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
4. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
5. Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio Breast Cancer Symposium
6. FDA Grants Orphan Drug Status To Eisais Lenvatinib
7. Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems
8. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
9. Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology
10. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
11. FDA Grants Orphan Drug Status To Eisais Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO), is ... residents. Naloxone is available without ... retail pharmacy, G-3320 Beecher Road. ... Drug Administration, is intended to block or reverse the ... loss of consciousness. The medication is often carried by ...
(Date:8/11/2017)... -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... today announced that it will release its second quarter ... conference call at 9:00am ET. The Company will discuss ... its strategy and outlook for the remainder of 2017. The ... , Chief Executive Officer, and Zvi Ben-David , ...
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... “Three Narrow Roads”: a vivid ... creation of published author, Rev. Dr. Burnett King Sr., is currently the pastor-teacher-visionary at ... of the Faith Track Club, Inc., a track-and-field program geared towards youth. , King ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Depressed: Super Heroes of the Bible”: ... upon the stories and the relevance these tales may have on the reader’s life. ... a former special education teacher, Jessica spends much of her time enjoying nature and ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Kingdom Mandate for Kingdom Builders”: a call to ... for Kingdom Builders” is the creation of published author, John F. McGeorge, Jr. ... a missionary in 1983. He spent three decades training pastors and Christian leaders. ...
(Date:8/18/2017)... ... 2017 , ... “Steve the Snake”: an entertaining and moral-based short story about ... published author, Harold Flash Haskins Jr., a husband, father and grandfather who served as ... “I write moral-based short stories for children and teens. My goal is to teach ...
(Date:8/17/2017)... ... 2017 , ... Riccobene Associates Family Dentistry, the Research Triangle’s ... its family of practices. Residents of Goldsboro will be able to experience the ... , Riccobene Associates Family Dentistry, founded by Dr. Michael Riccobene in 2000, prides ...
Breaking Medicine News(10 mins):